Abstract

High dimensional cytometry is an innovative tool for immune monitoring in health and disease, it has provided novel insight into the underlying biology as well as biomarkers for a variety of diseases. However, the analysis of large multiparametric datasets usually requires specialist computational knowledge. Here we describe ImmunoCluster (https://github.com/kordastilab/ImmunoCluster) an R package for immune profiling cellular heterogeneity in high dimensional liquid and imaging mass cytometry, and flow cytometry data, designed to facilitate computational analysis by a non-specialist. The analysis framework implemented within ImmunoCluster is readily scalable to millions of cells and provides a variety of visualization and analytical approaches, as well as a rich array of plotting tools that can be tailored to users' needs. The protocol consists of three core computational stages: 1, data import and quality control; 2, dimensionality reduction and unsupervised clustering; and 3, annotation and differential testing, all contained within an R-based open-source framework.

Data availability

The liquid mass cytometry dataset is avaiable from FlowRepository (http://flowrepository.org/id/FR-FCM-Z244).Imaging and flow cytometry datasets have been deposited to Dryad under the following DOIs: 10.5061/dryad.gf1vhhmpr, 10.5061/dryad.4b8gthtcf, 10.5061/dryad.3n5tb2rhd

The following data sets were generated
The following previously published data sets were used

Article and author information

Author details

  1. James W Opzoomer

    School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences and Medicine,, King's College London, London, United Kingdom
    Competing interests
    No competing interests declared.
  2. Jessica A Timms

    School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences and Medicine,, King's College London, London, United Kingdom
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-3687-9312
  3. Kevin Blighe

    School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences and Medicine,, King's College London, London, United Kingdom
    Competing interests
    No competing interests declared.
  4. Thanos P Mourikis

    School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences and Medicine,, King's College London, London, United Kingdom
    Competing interests
    No competing interests declared.
  5. Nicolas Chapuis

    Institut Cochin, Institut National de la Santé et de la Recherche Médicale U1016, Centre National de la Recherche Scientifique, Unité Mixte de Recherche 8104, Université, Université Paris Descartes, Paris, France
    Competing interests
    No competing interests declared.
  6. Richard Bekoe

    UCL Cancer Institute, Paul O'Gorman Building, University College London, London, United Kingdom
    Competing interests
    No competing interests declared.
  7. Sedigeh Kareemaghay

    School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences and Medicine,, King's College London, London, United Kingdom
    Competing interests
    No competing interests declared.
  8. Paola Nocerino

    School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences and Medicine,, King's College London, London, United Kingdom
    Competing interests
    No competing interests declared.
  9. Benedetta Apollonio

    School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences and Medicine,, King's College London, London, United Kingdom
    Competing interests
    No competing interests declared.
  10. Alan G Ramsay

    School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences and Medicine,, King's College London, London, United Kingdom
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-0452-0420
  11. Mahvash Tavassoli

    School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences and Medicine,, King's College London, London, United Kingdom
    Competing interests
    No competing interests declared.
  12. Claire Harrison

    School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences and Medicine; Haematology Department, Guy's Hospital, London, SE1 1UL, United Kingdom, King's College London, London, United Kingdom
    Competing interests
    No competing interests declared.
  13. Francesca D Ciccarelli

    Comprehensive Cancer Centre, King's College London, London, United Kingdom
    Competing interests
    No competing interests declared.
  14. Peter Parker

    School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences and Medicine; Francis Crick Institute, 1 Midland Road, London NW1 1AT, United Kingdom, King's College London, London, United Kingdom
    Competing interests
    No competing interests declared.
  15. Michaela Fontenay

    Institut Cochin, Institut National de la Santé et de la Recherche Médicale U1016, Centre National de la Recherche Scientifique, Unité Mixte de Recherche 8104, Université, Université Paris Descartes, Paris, France
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5492-6349
  16. Paul R Barber

    Molecular Oncology Group, UCL Cancer Institute, University College London, London, United Kingdom
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-8595-1141
  17. James N Arnold

    School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences and Medicine,, King's College London, London, United Kingdom
    For correspondence
    james.n.arnold@kcl.ac.uk
    Competing interests
    No competing interests declared.
  18. Shahram Kordasti

    School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences and Medicine,, King's College London, London, United Kingdom
    For correspondence
    shahram.kordasti@kcl.ac.uk
    Competing interests
    Shahram Kordasti, Honoraria: Beckman Coulter, GWT-TUD, Alexion. Consulting or Advisory Role: Syneos Health.Research Funding: Celgene, Novartis pharmaceutical.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-0347-4207

Funding

Cancer Research UK (A29283)

  • Jessica A Timms
  • Shahram Kordasti

Aplastic Anemia and MDS International Foundation

  • Jessica A Timms
  • Shahram Kordasti

Blood Cancer UK

  • Jessica A Timms
  • Shahram Kordasti

H2020 European Research Council (335326)

  • James W Opzoomer
  • James N Arnold

Medical Research Council (MR/N013700/1)

  • James W Opzoomer

Medical Research Council (Doctoral Training Partnership in Biomedical Sciences)

  • James W Opzoomer

Rosetrees Trust (M117-F2)

  • Sedigeh Kareemaghay
  • Mahvash Tavassoli

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Human subjects: Formalin-fixed paraffin-embedded (FFPE) DLBCL tumor tissue was obtained from King's College Hospital, in accordance with the Declaration of Helsinki and approved by the UK National Research Ethics Committee (reference 13/NW/0040).Head and neck squamous cell carcinoma (HNSCC) tissue was obtained from King's College Hospital, consent was attained by the King Guy's & St Thomas' Research Biobank, within King's Health Partners Integrated Cancer Centre.The non-interventional study which collected bone marrow samples from elderly healthy donors was approved by the ethical committee of Cochin-Port Royal Hospital (Paris, France) (CLEP Decision N{degree sign}: AAA-2020-08039).

Copyright

© 2021, Opzoomer et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 4,119
    views
  • 426
    downloads
  • 17
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. James W Opzoomer
  2. Jessica A Timms
  3. Kevin Blighe
  4. Thanos P Mourikis
  5. Nicolas Chapuis
  6. Richard Bekoe
  7. Sedigeh Kareemaghay
  8. Paola Nocerino
  9. Benedetta Apollonio
  10. Alan G Ramsay
  11. Mahvash Tavassoli
  12. Claire Harrison
  13. Francesca D Ciccarelli
  14. Peter Parker
  15. Michaela Fontenay
  16. Paul R Barber
  17. James N Arnold
  18. Shahram Kordasti
(2021)
ImmunoCluster provides a computational framework for the non-specialist to profile high- dimensional cytometry data
eLife 10:e62915.
https://doi.org/10.7554/eLife.62915

Share this article

https://doi.org/10.7554/eLife.62915

Further reading

    1. Computational and Systems Biology
    2. Neuroscience
    Anna Cattani, Don B Arnold ... Nancy Kopell
    Research Article

    The basolateral amygdala (BLA) is a key site where fear learning takes place through synaptic plasticity. Rodent research shows prominent low theta (~3–6 Hz), high theta (~6–12 Hz), and gamma (>30 Hz) rhythms in the BLA local field potential recordings. However, it is not understood what role these rhythms play in supporting the plasticity. Here, we create a biophysically detailed model of the BLA circuit to show that several classes of interneurons (PV, SOM, and VIP) in the BLA can be critically involved in producing the rhythms; these rhythms promote the formation of a dedicated fear circuit shaped through spike-timing-dependent plasticity. Each class of interneurons is necessary for the plasticity. We find that the low theta rhythm is a biomarker of successful fear conditioning. The model makes use of interneurons commonly found in the cortex and, hence, may apply to a wide variety of associative learning situations.

    1. Cancer Biology
    2. Computational and Systems Biology
    Rosalyn W Sayaman, Masaru Miyano ... Mark LaBarge
    Research Article

    Effects from aging in single cells are heterogenous, whereas at the organ- and tissue-levels aging phenotypes tend to appear as stereotypical changes. The mammary epithelium is a bilayer of two major phenotypically and functionally distinct cell lineages: luminal epithelial and myoepithelial cells. Mammary luminal epithelia exhibit substantial stereotypical changes with age that merit attention because these cells are the putative cells-of-origin for breast cancers. We hypothesize that effects from aging that impinge upon maintenance of lineage fidelity increase susceptibility to cancer initiation. We generated and analyzed transcriptomes from primary luminal epithelial and myoepithelial cells from younger <30 (y)ears old and older >55y women. In addition to age-dependent directional changes in gene expression, we observed increased transcriptional variance with age that contributed to genome-wide loss of lineage fidelity. Age-dependent variant responses were common to both lineages, whereas directional changes were almost exclusively detected in luminal epithelia and involved altered regulation of chromatin and genome organizers such as SATB1. Epithelial expression of gap junction protein GJB6 increased with age, and modulation of GJB6 expression in heterochronous co-cultures revealed that it provided a communication conduit from myoepithelial cells that drove directional change in luminal cells. Age-dependent luminal transcriptomes comprised a prominent signal that could be detected in bulk tissue during aging and transition into cancers. A machine learning classifier based on luminal-specific aging distinguished normal from cancer tissue and was highly predictive of breast cancer subtype. We speculate that luminal epithelia are the ultimate site of integration of the variant responses to aging in their surrounding tissue, and that their emergent phenotype both endows cells with the ability to become cancer-cells-of-origin and represents a biosensor that presages cancer susceptibility.